NYSE:CANF Can-Fite BioPharma (CANF) Stock Forecast, Price & News $2.59 +0.10 (+4.02%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$2.48▼$2.6250-Day Range$2.49▼$3.1252-Week Range$1.52▼$9.00Volume3,038 shsAverage Volume48,287 shsMarket Capitalization$9.17 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media About Can-Fite BioPharma (NYSE:CANF) StockCan-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Read More CANF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CANF Stock News HeadlinesSeptember 19, 2023 | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Earns Hold Rating from Analysts at StockNews.comSeptember 7, 2023 | finance.yahoo.comCan-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual ConferenceSeptember 27, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.September 1, 2023 | seekingalpha.comCan-Fite Biopharma discloses $100M mixed shelf offering - filingAugust 31, 2023 | finance.yahoo.comCan-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAugust 24, 2023 | businesswire.comCan-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating ...August 24, 2023 | finance.yahoo.comCan-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe SyndromeAugust 18, 2023 | markets.businessinsider.comCan-Fite Submits Pediatric Study Plan To Allow Registration Of PiclidenosonSeptember 27, 2023 | Stansberry Research (Ad)A 73-Year-Old Market Signal With 95% Accuracy Just FlashedThis signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.August 18, 2023 | finance.yahoo.comCan-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with PsoriasisJuly 17, 2023 | finance.yahoo.comCan-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer FoundationJuly 11, 2023 | finance.yahoo.comPresenting on the Emerging Growth Conference on July 12 & 13 Register NowJuly 7, 2023 | finance.yahoo.comCan-Fite to Present at the Emerging Growth Conference on July 13, 2023June 29, 2023 | finance.yahoo.comCan-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration PlanJune 27, 2023 | thestreet.comCan-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical DataJune 13, 2023 | msn.comCANF Rises on IND Submission Plans in Pancreatic CancerJune 13, 2023 | markets.businessinsider.comCan-Fite To Seek FDA Clearance For Phase II Trial Of Namodenoson In Pancreatic CancerJune 13, 2023 | finance.yahoo.comCan-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with NamodenosonJune 2, 2023 | finance.yahoo.comCan-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in BostonJune 1, 2023 | finance.yahoo.comCan-Fite Reports First Quarter 2023 Financial Results & Provides Clinical UpdateMay 30, 2023 | finance.yahoo.comCan-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)May 15, 2023 | benzinga.comCan-Fite: Presenting Namodenoson's New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023May 15, 2023 | finance.yahoo.comCan-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023May 11, 2023 | markets.businessinsider.comPre-market Movers: GFAI, SONO, KLXE, CDNA, DMRC…May 10, 2023 | finance.yahoo.comAll You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to BuyMay 2, 2023 | finance.yahoo.comInhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite ScientistsApril 26, 2023 | finanznachrichten.deCAN-FITE BIOPHARMA LTD ADRSee More Headlines Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CANF Company Calendar Last Earnings8/31/2023Today9/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:CANF CUSIPN/A CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees8Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.00 High Stock Price Forecast$34.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+788.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,170,000.00 Net Margins-1,231.78% Pretax Margin-1,255.93% Return on Equity-143.29% Return on Assets-84.01% Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick Ratio4.63 Sales & Book Value Annual Sales$810,000.00 Price / Sales11.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book1.95Miscellaneous Outstanding Shares3,540,000Free Float3,512,000Market Cap$9.17 million OptionableNot Optionable Beta1.30 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Pnina Fishman Ph.D. (Age 75)Founder, Chief Scientific Officer & Exec. Chairman Comp: $644kMr. Motti Farbstein (Age 59)CEO & Chief Operating and Financial Officer Comp: $414kDr. Sari Fishman Ph.D. (Age 51)VP of Bus. Devel. Comp: $325kDr. Ilan Cohn Ph.D. (Age 69)Co-Founder & Director Dr. Stephen A. Harrison FACPM.D., Member of Clinical Advisory Board & Consulting Chief Medical OfficerKey CompetitorsVirpax PharmaceuticalsNASDAQ:VRPXCyclerion TherapeuticsNASDAQ:CYCNBlue Water BiotechNASDAQ:BWVCadrenal TherapeuticsNASDAQ:CVKDBionomicsNASDAQ:BNOXView All Competitors CANF Stock - Frequently Asked Questions Should I buy or sell Can-Fite BioPharma stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CANF shares. View CANF analyst ratings or view top-rated stocks. What is Can-Fite BioPharma's stock price forecast for 2023? 2 Wall Street research analysts have issued 12 month price objectives for Can-Fite BioPharma's stock. Their CANF share price forecasts range from $12.00 to $34.00. On average, they predict the company's share price to reach $23.00 in the next year. This suggests a possible upside of 788.0% from the stock's current price. View analysts price targets for CANF or view top-rated stocks among Wall Street analysts. How have CANF shares performed in 2023? Can-Fite BioPharma's stock was trading at $0.6130 on January 1st, 2023. Since then, CANF shares have increased by 322.5% and is now trading at $2.59. View the best growth stocks for 2023 here. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) posted its quarterly earnings results on Thursday, August, 31st. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.14. The company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,231.78% and a negative trailing twelve-month return on equity of 143.29%. When did Can-Fite BioPharma's stock split? Can-Fite BioPharma shares reverse split before market open on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Can-Fite BioPharma's stock symbol? Can-Fite BioPharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "CANF." How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Can-Fite BioPharma's stock price today? One share of CANF stock can currently be purchased for approximately $2.59. How much money does Can-Fite BioPharma make? Can-Fite BioPharma (NYSE:CANF) has a market capitalization of $9.17 million and generates $810,000.00 in revenue each year. The company earns $-10,170,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis. How can I contact Can-Fite BioPharma? Can-Fite BioPharma's mailing address is 10 Bareket Street, Kiryat Matalon PO Box 7537, Petah Tikva 4951778, Israel. The official website for the company is www.canfite.com. The company can be reached via phone at 972-3-924-1114, via email at info@canfite.co.il, or via fax at 972-3924-9378. This page (NYSE:CANF) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.